US Stock Insider Trading | TransMedics Group disclosed 8 insider transactions on March 4

K-LinePoet · 2026-04-01T19:10:33+00:00

TransMedics Group disclosed multiple insider transactions on March 4, 2026, with executive Hernandez Gerardo engaging in multiple buy and sell transactions on the same day, involving the purchase of 5,912 shares and the sale of 7,236 shares. The company focuses on providing innovative organ transplant treatment solutions for patients with end-stage organ failure.

K-LinePoet

2026-04-01 19:10:33

Abstract generation in progress

On March 4, 2026, TransMedics Group (TMDX) disclosed 8 transactions by company insiders. Executive Hernandez Gerardo sold 5,912 shares on March 4, 2026.

[Recent Insider Transactions]

Disclosure date	Position	Name	Transaction date	Buy/Sell	Quantity	Price per share/USD	Total amount/USD
March 4, 2026	Executive	Corcoran Nicholas	March 2, 2026	Sell	2966	139.12	$412,600
March 4, 2026	Executive	Hernandez Gerardo	March 4, 2026	Sell	7236	147.21	$1,065,200
March 4, 2026	Executive	Corcoran Nicholas	January 23, 2026	Sell	984	135.30	$133,100
March 4, 2026	Executive	Hernandez Gerardo	March 4, 2026	Buy	5912	69.84	$412,900
March 4, 2026	Executive	Hernandez Gerardo	March 4, 2026	Buy	1324	77.12	$102,100
March 4, 2026	Executive	Ranganath Anil P.	March 2, 2026	Sell	864	139.12	$120,200
March 4, 2026	Executive	Hernandez Gerardo	March 2, 2026	Sell	375	139.12	$52,200
December 5, 2025	Executive	Hernandez Gerardo	December 4, 2025	Sell	920	139.62	$128,500
December 5, 2025	Director	Weill David	December 3, 2025	Sell	5000	138.64	$693,200
December 5, 2025	Director	Weill David	December 3, 2025	Buy	5000	14.20	$71,000

[Company Profile]

TransMedics Group, Inc. was registered in August 1998. The company is a commercial-stage medical technology company that provides organ transplantation therapy for patients with end-stage organ failure across multiple disease states. The company developed a network to replace the standard of care maintained for decades. The company’s innovative network technology replicates many aspects of the natural life and functional environment of external human organs. OCS represents a shift in how organ transplantation is preserved—from a static state to a dynamic environment—enabling new functions, including organ optimization and assessment.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes